Molecular Response has introduced TargetX platform for the rapid discovery and validation of new oncology targets. The integrated platform, which features 144,000 living tumor specimens, genomic databases and patient derived tumor models, ...
Tags: TargetX platform, oncology targets
Vernalis has reached a research milestone as part of the oncology drug discovery alliance with French pharmaceutical company, Servier. Under the drug discovery program, Vernalis will receive a payment of €0.5m from Servier on ...
Tags: drug discovery platforms, oncology drug discovery, undisclosed oncology